Literature DB >> 7751054

Differentiation of the O-2A progenitor cell line CG-4 into oligodendrocytes and astrocytes following transplantation into glia-deficient areas of CNS white matter.

R J Franklin1, S A Bayley, R Milner, C Ffrench-Constant, W F Blakemore.   

Abstract

The in vitro properties of the CG4 cell line have led to its increasing use as a cell line with which to study the behaviour of the O-2A progenitor cell. In this study we have examined the in vivo behaviour of the CG4 cell line following transplantation into areas of adult rat spinal cord white matter which have been permanently depleted of glial cells by the combination of local X-irradiation and direct injection of 0.1% ethidium bromide. Twenty-one days after transplantation, both myelin-forming oligodendrocytes and glial fibrillary acidic protein-positive astrocytes were identified within the lesion, indicating that the CG4 cell line has bipotential differentiation properties when introduced into a pathological environment consisting of demyelinated axons but devoid of oligodendrocytes or astrocytes. In this respect, the CG4 cell line resembles other glial progenitor cell lines that have been transplanted into similar lesions. In some areas of the lesion, remyelination was observed that was similar in extent to that achieved by growth factor-expanded populations of O-2A progenitor cells. The transplant origin of the cell types within the lesion was confirmed by retroviral incorporation of the lacZ marker gene, the expression of which allowed their identification by histochemistry. In conclusion, the in vivo properties of the CG4 cell line make it a highly suitable line with which to study the behaviour of O-2A progenitors following transplantation into normal and damaged CNS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7751054     DOI: 10.1002/glia.440130105

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  21 in total

1.  Proliferation of NG2-positive cells and altered oligodendrocyte numbers in the contused rat spinal cord.

Authors:  D M McTigue; P Wei; B T Stokes
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

2.  Temporal and quantitative expression of the myelin-associated lipids, ethanolamine plasmalogen, galactocerebroside, and sulfatide, in the differentiating CG-4 glial cell line.

Authors:  E Bichenkov; J S Ellingson
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

Review 3.  Glial cells: old cells with new twists.

Authors:  Ugo Ndubaku; Maria Elena de Bellard
Journal:  Acta Histochem       Date:  2007-12-18       Impact factor: 2.479

4.  A quantitative morphometric analysis of rat spinal cord remyelination following transplantation of allogenic Schwann cells.

Authors:  Karen L Lankford; Toshio Imaizumi; Osamu Honmou; Jeffery D Kocsis
Journal:  J Comp Neurol       Date:  2002-02-11       Impact factor: 3.215

5.  Cell Therapy From Bench to Bedside Translation in CNS Neurorestoratology Era.

Authors:  Hongyun Huang; Lin Chen; Paul Sanberg
Journal:  Cell Med       Date:  2010-01-01

Review 6.  Glial lineages and myelination in the central nervous system.

Authors:  A Compston; J Zajicek; J Sussman; A Webb; G Hall; D Muir; C Shaw; A Wood; N Scolding
Journal:  J Anat       Date:  1997-02       Impact factor: 2.610

Review 7.  Transplanting oligodendrocyte progenitors into the adult CNS.

Authors:  R J Franklin; W F Blakemore
Journal:  J Anat       Date:  1997-01       Impact factor: 2.610

Review 8.  Glial grafting for demyelinating disease.

Authors:  V Tepavcević; W F Blakemore
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

Review 9.  Mechanisms of cellular plasticity in cerebral perivascular region.

Authors:  N Egawa; J Lok; K Arai
Journal:  Prog Brain Res       Date:  2016-04-07       Impact factor: 2.453

Review 10.  Choosing drug therapy for multiple sclerosis. An update.

Authors:  B W van Oosten; L Truyen; F Barkhof; C H Polman
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.